Teva Pharmaceutical Industries (TEVA) Non Operating Income (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Non Operating Income for 18 consecutive years, with -$224.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income rose 11.11% year-over-year to -$224.0 million; the trailing twelve-month figure through Jun 2026 stood at -$897.0 million (up 7.24% YoY), and the FY2025 full-year result was -$934.0 million, up 4.79% from the prior year.
• Non Operating Income retreated to -$224.0 million in Q2 2026 per TEVA's latest filing, from -$216.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at -$211.0 million in Q2 2022 and bottomed at -$280.0 million in Q3 2023.
• Historically, Non Operating Income has averaged -$243.2 million across 5 years, with a median of -$247.0 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income gained 22.99% in 2022, then dropped 27.01% in 2023.
• Over 5 years, Non Operating Income stood at -$245.0 million in 2022, then decreased by 1.63% to -$249.0 million in 2023, then gained by 12.45% to -$218.0 million in 2024, then decreased by 0.92% to -$220.0 million in 2025, then fell by 1.82% to -$224.0 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$224.0 million, -$216.0 million, and -$220.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.